A dysfunctional signaling pathway in the hippocampus has been linked to chronic pain-related memory impairment in mice.

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

Experts discuss the current research on the use of digital therapeutics for managing chronic pain in rheumatic disease.

The consensus on mechanisms underlying chronic pain -- pain that persists for more than 3 months, which affects 21% of U.S. adults-- is even less clear. The PAF and CME signature "will likely have ...

Chronic Pain, that persists beyond the usual recovery period or occurs along with a chronic <a target=_blank href= ...

The US Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...

The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...

Federal officials have approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S.